Details

Autor(en) / Beteiligte

• Giommoni, E.
• Milella, M.
• Di Marco, M.C.
• Spada, M.
• Cordio, S.
• Aprile, G.
• Ghidini, M.
• Bozzarelli, S.
• Macchini, M.
• Orsi, G.
• Rulli, Er
• Porcu, L.
• Reni, Michele
• Macchini, Marina
• Orsi, Giulia
• Peretti, Umberto
• Valente, Mariamaddalena
• Bergamo, Francesca
• Zagonel, Vittorina
• Lonardi, Sara
• Buggin, Federica
• Milella, Michele
• Cavanna, Luigi
• Di Nunzio, Camilla
• Di Marco, Maria Cristina
• Spada, Massimiliano
• Messina, Marco
• Cordio, Stefano
• Avola, Francesco
• Aprile, Giuseppe
• Majer, Federica
• Artioli, Fabrizio
• Pasqualini, Antonella
• Ghidini, Michele
• Lazzarelli, Silvia
• Bozzarelli, Silvia
• Sala, Simona
• Pettorelli, Elisa
• Salmaso, Flavia
• Basso, Marco
• Silvestris, Nicola
• Del Curatolo, Sabina
• Zustovich, Fable
• Longobardi, Ciro
• Sandi, Ilenia
• Montelatici, Silvia
• Giordano, Monica
• Gilardoni, Micol
• Tamburini, Emiliano
• Rudnas, Britt
• Negrini, Giorgia
• Vici, Elio Maria
• Marabese, Alessandra
• Garetto, Cristina
• Cinieri, Saverio
• Fumi, Guglielmo
• Isidori, Agnese
• Ciccarese, Giovanni
• Paolo Frassineti, Giovanni Luca
• Pagan, Flavia
• Vaccaro, Vanja
• Spoto, Chiara
• Salani, Francesca
• Barone, Elisa
• Berardi, Rossana
• Onofri, Azzurra
• Ballatore, Zelmira
• Scipioni, Teresa
• Marrapese, Giovanna
• Idotta, Laura
• Lonati, Veronica
• Ceribelli, Anna
• Zannori, Cristina
• Bassanelli, Maria
• Ginocchi, Laura
• Orlandi, Massimo
• Niger, Monica
• Tamberi, Stefano
• Papiani, Giorgio
• Valli, Irene
• Allione, Paolo
• Boe, Maria Giovanna
• Lai, Eleonora
• Pireddu, Annagrazia
• Ziranu, Pina
• Demurtas, Laura
• Mariani, Stefano
• Pretta, Andrea
• Malaspina, Valentina
• Tonini, Giuseppe
• Grassani, Teresa
• Pierosandro, Tagliaferri
• Ierardi, Antonella
• Torri, Valter
• Porcu, Luca
• Rulli, Erica
• De Simone, Irene
• Carlucci, Luciano
• Poli, Davide
• Tonto, Paola

Titel

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Ist Teil von

• ESMO open, 2023-02, Vol.8 (1), p.100777-100777, Article 100777

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2023

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Information about the adherence to scientific societies guidelines in the ‘real-world’ therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative to 2017-2018 recommendations of the Italian Association of Medical Oncology (AIOM). Treatment-naive adult patients with pancreatic adenocarcinoma were enrolled. Group A received adjuvant therapy, group B received primary chemotherapy, and group C had metastatic disease. The results on patients accrued until 31 October 2019 with a mature follow-up were presented. Since July 2017, 833 eligible patients of 923 (90%) were enrolled in 44 Italian centers. The median age was 69 years (range 36-89 years; 24% >75 years); 48% were female; 93% had Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; group A: 16%, group B: 30%; group C: 54%; 72% Nord, 13% Center, 15% South. In group A, guidelines adherence was 68% [95% confidence interval (CI) 59% to 76%]; 53% of patients received gemcitabine and 15% gemcitabine + capecitabine; median CA19.9 was 29 (range 0-7300; not reported 15%); median survival was 36.4 months (95% CI 27.5-47.3 months). In group B, guidelines adherence was 96% (95% CI 92% to 98%); 55% of patients received nab-paclitaxel + gemcitabine, 27% FOLFIRINOX, 12% gemcitabine, and 3% clinical trial; median CA19.9 was 337 (range 0-20220; not reported 9%); median survival was 18.1 months (95% CI 15.6-19.9 months). In group C, guidelines adherence was 96% (95% CI 94% to 98%); 71% of patients received nab-paclitaxel + gemcitabine, 16% gemcitabine, 8% FOLFIRINOX, and 4% clinical trial; liver and lung metastases were reported in 76% and 23% of patients, respectively; median CA19.9 value was 760 (range 0-1374500; not reported 9%); median survival was 10.0 months (95% CI 9.1-11.1 months). The GARIBALDI survey shows a very high rate of adherence to guidelines and survival outcome in line with the literature. CA19.9 testing should be enhanced; nutritional and psychological counseling represent an unmet need. Enrollment to assess adherence to updated AIOM guidelines is ongoing. •This survey evaluates the agreement with national recommendations included in 2017-2018 AIOM guidelines.•A total of 833 eligible patients with pancreatic adenocarcinoma were included; grouped in 3 settings, according to the type of treatment.•The study shows a very high rate of adherence to guidelines and survival outcome in line with the literature.